{
  "abstract": "Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterised by progressive inflammation and fibrosis of the bile ducts, leading to biliary cirrhosis and an increased risk of cholangiocarcinoma. PSC is commonly associated with inflammatory bowel disease (IBD). The pathogenesis of PSC is complex and not fully understood, but immune-mediated mechanisms, particularly T cell involvement, are believed to play a central role.",
  "authors": [
    {
      "affiliations": [
        "Department of Anaesthesia and Intensive Care and Peter Hung Pain Research Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong"
      ],
      "name": "Likai Tan"
    },
    {
      "affiliations": [
        "Department of Anaesthesia and Intensive Care and Peter Hung Pain Research Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong",
        "State Key Laboratory of Digestive Disease and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, Hong Kong"
      ],
      "name": "William Ka Kei Wu"
    }
  ],
  "title": "24-Nor-ursodeoxycholic acid: a novel treatment targeting T-cell-mediated immune dysregulation in primary sclerosing cholangitis and beyond",
  "uid": "ac111a69-7f8e-54b3-a73b-f572c4eb70a3"
}